Explaining the VA's New Antidepressant Consent Form

Consider an illustrative example. Once the requirements the Department of Veterans Affairs announced on September 28 take effect, a 27-year-old veteran with a second episode of major depression who agrees to start sertraline in a VA clinic will need patient education and a signed consent form, because the antidepressant is being prescribed to a veteran younger than 30. The psychiatrist was already expected to discuss risks, benefits and alternatives before prescribing. What changes is that the discussion becomes standardized, documented in a specified way and, for this veteran, signed.

The veteran may reasonably ask why, and may hear a form that appears only for people under 30 as a warning that the medication is more dangerous at 27 than at 31. The answer has to neither inflate nor dismiss the risk the label describes.

The VA announcement describes new guidance for psychotropic medications, which it defines to include antipsychotics, stimulants, antidepressants, anxiolytics and opioids. It notes that current practice already includes "a full discussion of the risks, side effects, benefits and alternatives" and signature consent for all long-term opioid treatment. Starting in 2027, it adds:

The VA says it will spend the rest of 2026 training staff and updating policies and procedures. The announcement sets 2027 as the start but gives no specific date within it, and it names no revised directive. In the public sources checked on October 20 (the VA newsroom, the VHA publications index and the current text of the informed consent directive), no implementing revision, education materials or clarification was located; internal VA guidance is outside that check. The announcement also does not say whether a veteran already taking an antidepressant at 26 will need a new signature, or whether a dose change, a switch or a renewal triggers one.

Signature consent is not new in the VA, and it is not limited to whole drug classes. The current informed consent directive, VHA Directive 1004.01, requires signatures for treatments that involve sedation, anesthesia or narcotic analgesia, significant discomfort, significant risk of complication or morbidity, or injection into a joint space or body cavity. The same criteria appear in the VA regulation. The directive maintains a list of treatments that meet those criteria, provides a process for updating it, and allows the criteria to be applied to an individual patient whose circumstances raise the risk. It also states that signature consent is not permitted outside the criteria, because "the extra documentation burden on the patient is ethically unjustifiable."

The VA has now signaled that, for antidepressants under 30 and opioid-benzodiazepine co-prescribing, it considers the added documentation warranted. The public materials checked do not say whether it will do this by placing those categories on the existing list under the risk criteria, by amending the directive, or by some other route. That is an implementation question, not evidence of a regulatory conflict, and the answer will determine details clinicians care about, including how the rule handles patients already in treatment.

The antidepressant boxed warning states that antidepressants "increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies." The box itself gives no age number; the patient Medication Guide refers to people "24 years of age and younger."

That boundary traces to the FDA's pooled analysis of 372 placebo-controlled trials in 99,231 adults, published by Stone and colleagues in 2009. Among adults with psychiatric indications, the odds ratio for suicidal ideation or worse with antidepressants versus placebo was 1.62 (95% CI 0.97 to 2.71) under age 25, and for suicidal behavior 2.30 (1.04 to 5.09). The analysis did not report a 25 to 29 group. Its next band, ages 25 to 34, had odds ratios of 0.76 (0.53 to 1.08) for ideation or worse and 0.81 (0.43 to 1.52) for suicidal behavior. Those broader estimates have wide intervals that include no difference, and they do not resolve risk specifically at ages 25 to 29. The authors also cautioned that patients at highest suicide risk are "extremely unlikely" to enter placebo-controlled trials and that most included studies observed initial acute treatment over eight to 10 weeks.

So the VA's line at 30 extends beyond the age group the label highlights, and the announcement does not explain why. A documentation margin wider than a label's warning is a policy choice, not a new safety finding. For the 27-year-old, an accurate explanation might run: the VA asks everyone under 30 to sign for this medication, which reflects a VA policy choice rather than something found about you; the label's warning emphasizes pediatric and young adult patients; and, separately, the label asks clinicians to monitor everyone taking an antidepressant for worsening mood or new suicidal thoughts, especially early in treatment and after dose changes, which is why follow-up matters at any age.

The opioid-benzodiazepine trigger has a more direct regulatory anchor. In August 2016 the FDA required boxed warnings on prescription opioid analgesics, opioid cough products and benzodiazepines, nearly 400 products, after finding that combined use had caused serious harms including slowed or difficult breathing and deaths. For that combination, the more important conversation may precede the form: whether both medications are still needed together.

There is little direct evidence about signature consent for psychotropics. The closest natural experiment is the VA's own 2014 policy for long-term opioid therapy, which bundled standardized patient education, a discussion of risks, benefits and alternatives, a shared treatment plan and a written signature. Using national VA data and an interrupted time series, Avoundjian and colleagues compared three calendar periods: the year before the policy (May 2013 to May 2014), the year after it was issued, and the following year, when it was mandatory. Year 1 and Year 3 are policy periods, not three years of follow-up of the same patients. After adjustment for facility, opioid tier, facility-level consent coverage, seasonality and secular trends, veterans starting long-term opioid therapy in Year 3 were more likely than those in Year 1 to have any medical follow-up within 30 days (relative risk 1.12, 95% CI 1.10 to 1.13) and a primary care visit within three months (1.13, 1.12 to 1.15). The effect appeared to wane over time, and the authors note that other opioid-safety initiatives coincided with the policy and that residual confounding may remain.

Those results support a modest association between a bundled consent process and follow-up. They do not isolate the signature or measure comprehension, patient-reported experience or safety outcomes.

On comprehension, the evidence concerns how consent is delivered rather than whether it is signed. A 2020 updated systematic review of 52 studies of procedure consent found that about two thirds of interventions improved comprehension, and that interactive approaches, such as asking patients to repeat information back, appeared more effective than written or other non-interactive materials. Heterogeneity prevented a meta-analysis, 44% of studies had a high risk of bias, and most measured understanding of risks rather than benefits or alternatives. The review did not study psychotropic prescribing.

Veterans service organizations pushed for written consent, and the pending Written Informed Consent Act (H.R. 4837) and its Senate companion (S. 3314, introduced December 2, 2025) would extend the VA's opioid consent framework to antipsychotics, stimulants, antidepressants, anxiolytics and narcotics. The American Legion called the VA's narrower policy a first step; its statement quoted Mario Marquez: "Informed consent does not discourage treatment. Instead, it makes sure each veteran understands their choices and alternatives." The strongest version of the advocates' case does not depend on proving that signatures improve comprehension. It holds that a signature creates a deliberate decision point, sets out what a veteran was entitled to be told, gives the veteran a record of the choice, and reinforces the right to decline. Those are arguments about autonomy and accountability; they have not been tested as clinical effects, and they do not need to be in order to carry ethical weight.

Seven organizations, including the American Psychiatric Association, the American Academy of Family Physicians and Mental Health America, objected to the broader bill in a December 2, 2025 letter, warning that "imposing additional paperwork could delay care at precisely the moment when timely treatment is most critical" and that singling out these medications "risks reinforcing stigma around mental health treatment and may discourage veterans from initiating or continuing essential care." Those concerns were directed at signature requirements across most psychiatric drug classes. Like the Legion's assurance that consent does not discourage treatment, they are predictions, not measured effects of the narrower VA policy on whether veterans start or stay in treatment; that policy has not yet taken effect.

Once the requirements take effect, the form will be part of the visit. After explaining why it is there, the psychiatrist can shape the rest of the discussion, including whether it checks that the veteran understood the decision rather than only signed for it:

A signature at the end of that visit records that the discussion happened. It cannot show what the 27-year-old took from it.

Source note: VA policy details are quoted from the September 28, 2026 VA announcement. Public sources checked on October 20, 2026 did not include an implementing directive revision, education materials or a specific effective date within 2027; internal VA guidance was not accessible. Existing VHA policy is quoted from Directive 1004.01 (December 2023, as amended in 2024) and 38 CFR 17.32. Label wording is from the current Zoloft boxed warning, Medication Guide and Section 5.5. Age-group results are odds ratios from Table 6 of the FDA pooled analysis (Stone et al., BMJ 2009) in adults with psychiatric indications. The opioid consent evidence (Avoundjian et al., J Pain Res 2022) is an interrupted time series of a bundled consent policy measuring follow-up visits. The comprehension review (Glaser et al., Med Decis Making 2020) concerns medical and surgical procedures. Legislative status is from the Congress.gov API (H.R. 4837) and GovInfo bill status (S. 3314) as retrieved October 20, 2026; later actions may not be reflected. The opening case is a fictional composite for illustration.

Educational Disclaimer: The Psychiatric Record provides general educational information for psychiatric and mental-health professionals. Content does not constitute medical, legal, regulatory, compliance, billing, or other professional advice; does not establish a standard of care; and is not a substitute for independent professional judgment. Appropriate assessment and treatment depend on the individual, setting, and current authoritative guidance. Patients should coordinate treatment decisions with their treating clinicians.